Article thumbnail

Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine

By Xiancheng Zhang, Peng He, Zhongyu Hu, Xingtai Wang and Zhenglun Liang
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1998). AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
  2. (2009). AM: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology
  3. (2010). B: Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants.
  4. (2001). Bluestone JA: Complexities of Cd28/B7: ctla-4 co-stimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol
  5. (2008). BN: Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.
  6. (2011). D: HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine
  7. (2000). Decreased function of peripheral blood dendritic cells in patients with Zhang et al.
  8. (2010). Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. Gene Ther
  9. (1997). Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant
  10. (2009). Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination. Vaccine
  11. (2007). Failure to respond to hepatitis B vaccine in children with celiac disease.
  12. (1977). Favero MS: Viral hepatitis B: aspects of environmental control. Health Lab Sci
  13. (1997). Hepatitis B virus infection.
  14. (2007). Hogenesch H: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines
  15. (1990). HS: The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am
  16. (1994). Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.
  17. (2005). Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunnol
  18. (2006). Kołodziejczyk AM: Adjuvants–essential components of new generation vaccines. Postepy Biochem
  19. (2010). Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines
  20. (1997). Naoumov NV: Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.
  21. (2009). Olive C: Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. Vaccine
  22. (2008). Organization: Programmes and projects - Immunization service delivery and accelerated disease control - New vaccines and technologies - Hepatitis B.
  23. (2010). PH: Mode of action of adjuvants: implications for vaccine safety and design. Biologicals
  24. (2005). SL: Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine
  25. (2010). SS: Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. Hum Immunol
  26. (2001). The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol
  27. (2011). ZM: Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. Cell Stress Chaperones